Enanta Pharmaceuticals Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended June 30, 2013
Third Fiscal Quarter and Nine Months Ended
Revenue for the three months ended
Research and development expenses totaled
General and administrative expenses totaled
Net loss for the three months ended
Cash, cash equivalents and marketable securities totaled
“Our all oral, antiviral hepatitis C pipeline continues to progress with three compounds advancing in clinical development,” stated
Recent Developments
- Six Phase 3 registration studies that include ABT-450, Enanta and AbbVie’s collaborative protease inhibitor for hepatitis C (HCV), are fully enrolled, and a New Drug Application is expected to be filed in calendar 2Q 2014
- Combination studies of ABT-493 (Enanta and AbbVie’s next-generation collaborative protease inhibitor for HCV) with ABT-530 (AbbVie’s next-generation NS5A inhibitor) were recently initiated, and Phase 2 studies are expected to begin in 2013
- Enanta was added to the Russell 3000 and Russell 2000 Indexes on
June 28, 2013 - A proof-of-concept study of EDP-239 (Enanta’s NS5A inhibitor) was recently initiated by
Novartis , Enanta’s development partner for NS5A compounds for HCV
Upcoming Events and Presentations
Enanta management will participate at the following events:
August 12, 2013 : Jefferies 2013 Boston Healthcare Summit,Boston, MA September 3, 2013 : Citi’s 8th AnnualBiotech Conference ,Boston, MA September 11-12, 2013 : Stifel 2013 Healthcare Conference,Boston, MA
About Enanta
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to the prospects for further clinical development of ABT-450, ABT-493 and EDP-239 and the expected timeline for results of Phase 3 studies of regimens that include ABT-450. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta’s reliance on the development and commercialization efforts of
ENANTA PHARMACEUTICALS, INC CONDENSED STATEMENT OF OPERATIONS (In thousands, except per share amounts) |
|||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||
June 30, | June 30, | ||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
Revenue | $ | 1,649 | $ | 2,542 | $ | 30,704 | $ | 39,848 | |||||||||||||
Operating expenses | |||||||||||||||||||||
Research and development | 4,039 | 4,925 | 12,541 | 10,860 | |||||||||||||||||
General and administrative | 1,788 | 1,145 | 4,433 | 3,603 | |||||||||||||||||
Total operating expenses | 5,827 | 6,070 | 16,974 | 14,463 | |||||||||||||||||
Income from operations | (4,178) | (3,528) | 13,730 | 25,385 | |||||||||||||||||
Other income (expense) | |||||||||||||||||||||
Interest income | 64 | 48 | 146 | 77 | |||||||||||||||||
Interest expense | (7) | - | (23) | - | |||||||||||||||||
Change in fair value of warrant liability | (17) | (21) | 217 | (11) | |||||||||||||||||
Total other income (expense), net | 40 | 27 | 340 | 66 | |||||||||||||||||
Net income (loss) | (4,138) | (3,501) | 14,070 | 25,451 | |||||||||||||||||
Accretion of redeemable convertible preferred stock to redemption value | |||||||||||||||||||||
- | (1,330) | (2,526) | (4,035) | ||||||||||||||||||
Net income (loss) allocable to participating securities | - | - | (13,670) | (19,606) | |||||||||||||||||
Net income (loss) allocable to common stockholders | $ | (4,138) | $ | (4,831) | $ | (2,126) | $ | 1,810 | |||||||||||||
Net income (loss) per share allocable to common stockholders: | |||||||||||||||||||||
Basic | $ | (0.23) | $ | (4.31) | $ | (0.30) | $ | 1.68 | |||||||||||||
Diluted | $ | (0.23) | $ | (4.31) | $ | (0.30) | $ | 1.52 | |||||||||||||
Weighted average common shares outstanding: | |||||||||||||||||||||
Basic | 17,819,813 | 1,120,400 | 7,052,989 | 1,075,993 | |||||||||||||||||
Diluted | 17,819,813 | 1,120,400 | 7,052,989 | 2,436,637 | |||||||||||||||||
ENANTA PHARMACEUTICALS, INC CONDENSED BALANCE SHEET DATA (In thousands) |
|||||||||
June 30, | September 30, | ||||||||
2013 | 2012 | ||||||||
Assets | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 18,878 | $ | 10,511 | |||||
Short-term marketable securities | 75,668 | 33,251 | |||||||
Accounts receivable | 876 | 1,049 | |||||||
Unbilled receivables | 981 | 1,893 | |||||||
Prepaid expenses and other current assets | 1,463 | 604 | |||||||
Total current assets | 97,866 | 47,308 | |||||||
Property and equipment, net | 1,152 | 611 | |||||||
Long-term marketable securities | 20,217 | 1,656 | |||||||
Restricted cash | 436 | 436 | |||||||
Other assets | - | 2,151 | |||||||
Total assets | $ | 119,671 | $ | 52,162 | |||||
Liabilities and Stockholders' Equity (Deficit) | |||||||||
Current liabilities: | |||||||||
Accounts payable | $ | 918 | $ | 1,851 | |||||
Accrued expenses | 2,023 | 3,866 | |||||||
Deferred Revenue | - | 17 | |||||||
Total current liabilities | 2,941 | 5,734 | |||||||
Warrant liability | 1,784 | 2,001 | |||||||
Other long-term liabilities | 535 | 498 | |||||||
Total liabilities | 5,260 | 8,233 | |||||||
Redeemable convertible preferred stock | 158,955 | ||||||||
Convertible preferred stock | 327 | ||||||||
Total stockholders' equity (deficit) | 114,411 | (115,353) | |||||||
Total liabilities and stockholders' equity (deficit) | $ | 119,671 | $ | 52,162 | |||||
Source:
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR